drug_comps___3rd_world

drug_comps___3rd_world - Wednesday, August 21, 2002...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
Wednesday, August 21, 2002 Document Page: 1 Drug Makers and 3rd World: Study in Neglect New York Times ; New York, N.Y.; May 21, 2000; DONALD G. McNEIL Jr.; Sic: 8099 Sic: 923120 Sub Title: [Special Report] Edition: Late Edition (East Coast) Column Name: MEDICINE MERCHANTS: A special report. Start Page: 1.1 ISSN: 03624331 Subject Terms: Pharmaceutical industry Poverty Developing countries LDCs Dateline: OMUGO, Uganda Companies: World Health Organization Sic: 8099 Sic: 923120 Abstract: These ailments go untreated or badly treated not just because the poor cannot afford the drugs they need, though that is a serious problem, but because the drugs themselves do not exist. The pharmaceutical industry has little incentive to invent them. Companies decline to invest the huge sums needed to chase a cure they know their potential customers cannot afford. Pharmaceutical executives reluctantly concur with his assessment. Told that the industry's critics say it would rather find a cure for a bald American than a dying African, Francois Gros, a spokesman for Aventis, the French-German pharmaceutical company that makes three of the four sleeping sickness drugs, ruefully acknowledged: ''That's not completely wrong. We know what's happening in the third world, but we don't act.'' [Earlier this month, five major pharmaceutical companies announced that they were entering negotiations with the W.H.O. to voluntarily lower their prices on their AIDS drugs to Africa by as much as 80 percent. But last week, at a global convention of health ministers at the W.H.O.'s headquarters in Geneva, the ministers of many poor nations said that was not enough. They asked the W.H.O. to create a database of all prices for AIDS drugs, including the cheapest generics from countries that do not honor American or European patents, and to help them change their patent laws so they could buy them.] Full Text: Copyright New York Times Company May 21, 2000 Jabbing, apologizing and then jabbing again, it takes Harriet Ayikoru nearly 20 minutes to find a usable vein beneath the sleeves of the sad old Tweety Bird T-shirt that Sentina Drajiru wears, and when the melarsoprol goes in, Ms. Drajiru winces. Again and again she lightly touches her arm to show exactly where she feels the sharp tip of the pain as the medicine simmers up it. It is like eating chili peppers, she says, only it is inside her. ''Once you use this drug, the vein is spoiled,'' says Miss Ayikoru, a nurse in the thatched clinic here. ''As it is corrosive, it erodes the inside layer. So the relapses like her are the hardest cases -- the scar tissue is there even six months later.'' Melarsoprol, invented almost 70 years ago, is melarsen oxide dissolved in propylene glycol -- literally, arsenic in antifreeze. It kills 5 percent of those treated with it. But it is the only medicine available to treat advanced sleeping sickness, one of the historic scourges of Africa, which was nearly wiped out 50 years ago, but has made a comeback. The only alternative ran out in July. The manufacturer, which abandoned it as unprofitable when it turned out to be useless against its intended target, cancer, has made one last batch, enough for 1,000 patients. But
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 2
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 05/31/2009 for the course BIO 46 taught by Professor Broverman during the Fall '07 term at Duke.

Page1 / 3

drug_comps___3rd_world - Wednesday, August 21, 2002...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online